Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (441) 441
life sciences & biomedicine (439) 439
humans (364) 364
open-label (279) 279
female (249) 249
male (245) 245
adult (188) 188
middle aged (185) 185
treatment outcome (174) 174
aged (136) 136
neurosciences & neurology (127) 127
clinical neurology (116) 116
biological and medical sciences (88) 88
medical sciences (87) 87
care and treatment (85) 85
clinical trials (82) 82
psychiatry (81) 81
oncology (70) 70
drug therapy (69) 69
pharmacology & pharmacy (69) 69
pharmacology. drug treatments (63) 63
adolescent (60) 60
neurosciences (59) 59
neurology (56) 56
chemotherapy (55) 55
safety (55) 55
prospective studies (54) 54
patients (52) 52
analysis (51) 51
efficacy (51) 51
research (49) 49
young adult (47) 47
dose-response relationship, drug (46) 46
aged, 80 and over (45) 45
open-label study (44) 44
double-blind method (43) 43
quality of life (43) 43
multicenter (42) 42
drug therapy, combination (41) 41
general & internal medicine (41) 41
open-label trial (41) 41
cancer (40) 40
medical research (40) 40
double-blind (38) 38
medicine, general & internal (37) 37
medicine & public health (36) 36
time factors (36) 36
drug administration schedule (35) 35
open label (34) 34
medicine, experimental (33) 33
follow-up studies (32) 32
health aspects (32) 32
child (31) 31
medicine (31) 31
neuropharmacology (31) 31
social sciences (29) 29
schizophrenia (27) 27
severity of illness index (27) 27
clinical trial (26) 26
medicine, research & experimental (26) 26
pain (26) 26
research & experimental medicine (26) 26
abridged index medicus (25) 25
administration, oral (24) 24
dosage and administration (24) 24
open-label extension (24) 24
psychopharmacology (24) 24
studies (24) 24
therapy (24) 24
usage (24) 24
randomized controlled trials as topic (23) 23
surgery (23) 23
complications and side effects (22) 22
drugs (22) 22
epilepsy (22) 22
open‐label (22) 22
psychology (22) 22
tumors (22) 22
anticonvulsants - therapeutic use (21) 21
antipsychotic agents - therapeutic use (21) 21
metastasis (21) 21
patient outcomes (21) 21
pharmacology (21) 21
psychology. psychoanalysis. psychiatry (21) 21
survival (21) 21
treatment (21) 21
mutation (20) 20
original (20) 20
original research (20) 20
psychiatric status rating scales (20) 20
trial (20) 20
anticonvulsants - adverse effects (19) 19
children (19) 19
dermatology (19) 19
internal medicine (19) 19
research design (19) 19
risk factors (19) 19
seizures (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
lung neoplasms - drug therapy (17) 17
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (575) 575
German (7) 7
Japanese (5) 5
Portuguese (3) 3
Russian (2) 2
Chinese (1) 1
French (1) 1
Italian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
by Stupp, Roger and Taillibert, Sophie and Kanner, Andrew and Read, William and Steinberg, David M and Lhermitte, Benoit and Toms, Steven and Idbaih, Ahmed and Ahluwalia, Manmeet S and Fink, Karen and Di Meco, Francesco and Lieberman, Frank and Zhu, Jay-Jiguang and Stragliotto, Giuseppe and Tran, David D and Brem, Steven and Hottinger, Andreas F and Kirson, Eilon D and Lavy-Shahaf, Gitit and Weinberg, Uri and Kim, Chae-Yong and Paek, Sun-Ha and Nicholas, Garth and Bruna, Jordi and Hirte, Hal and Weller, Michael and Palti, Yoram and Hegi, Monika E and Ram, Zvi
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Mitosis | Humans | Middle Aged | Male | Electric Stimulation Therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Glioblastoma - surgery | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Temozolomide | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Chemotherapy | Usage | Patient outcomes | Dosage and administration | Drug therapy | Glioblastoma multiforme | Cancer | Statistical analysis | Toxicity | Glioblastoma | Central nervous system | Clinical trials | Cell division | Nervous system | Maintenance | Patients | Survival | Scalp | Skin | Portable equipment | Electric fields | Tumors | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
by Kim, Dong-Wan and Tiseo, Marcello and Ahn, Myung-Ju and Reckamp, Karen L and Hansen, Karin Holmskov and Kim, Sang-We and Huber, Rudolf M and West, Howard L and Groen, Harry J. M and Hochmair, Maximilian J and Leighl, Natasha B and Gettinger, Scott N and Langer, Corey J and Roiguez, Luis G. Paz-Ares and Smit, Egbert F and Kim, Edward S and Reichmann, William and Haluska, Frank G and Kerstein, David and Camidge, D. Ross
Journal of clinical oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2490 - 2498
AP26113 | POTENT | ALK INHIBITORS | SAFETY | CERITINIB | BRAIN METASTASES | RESISTANCE | OPEN-LABEL | CHEMOTHERAPY | PROGRESSION | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Young Adult | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Headache - chemically induced | Pyridines - therapeutic use | Crizotinib | Organophosphorus Compounds - adverse effects | Cough - chemically induced | Pyrimidines - administration & dosage | Organophosphorus Compounds - therapeutic use | Treatment Outcome | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Retreatment | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Aged | Organophosphorus Compounds - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
by Lind, Marcus and Hirsch, Irl B and Tuomilehto, Jaakko and Dahlqvist, Sofia and Ahrén, Bo and Torffvit, Ole and Attvall, Stig and Ekelund, Magnus and Filipsson, Karin and Tengmark, Bengt-Olov and Sjöberg, Stefan and Pehrsson, Nils-Gunnar and Institute of Medicine, Department of Molecular and Clinical Medicine and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Sahlgrenska akademin and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Institutionen för medicin
BMJ : British Medical Journal, ISSN 0959-8138, 10/2015, Volume 351, pp. h5364 - h5364
RESEARCH | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Weight Loss - drug effects | Patient Satisfaction | Hypoglycemic Agents - administration & dosage | Fasting - blood | Injections, Subcutaneous | Postprandial Period | Female | Drug Therapy, Combination | Hypoglycemia - chemically induced | Double-Blind Method | Drug Administration Schedule | Insulin - administration & dosage | Treatment Outcome | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Aged | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Index Medicus | Abridged Index Medicus | glycemic control | once-daily lixisenatide | basal insulin | Endokrinologi och diabetes | adding liraglutide | open-label trial | parallel-group | statement | european association | position | blood-glucose control | Endocrinology and Diabetes | exenatide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
by Taieb, Julien, Prof and Tabernero, Josep, Prof and Mini, Enrico, Prof and Subtil, Fabien, PhD and Folprecht, Gunnar, MD and Van Laethem, Jean-Luc, Prof and Thaler, Josef, Prof and Bridgewater, John, MD and Petersen, Lone Nørgård, Prof and Blons, Hélène, PhD and Collette, Laurence, PhD and Van Cutsem, Eric, Prof and Rougier, Philippe, Prof and Salazar, Ramon, Prof and Bedenne, Laurent, Prof and Emile, Jean-François, Prof and Laurent-Puig, Pierre, Prof and Lepage, Come, Prof and PETACC-8 Study Investigators
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 862 - 873
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Infusions, Intravenous - adverse effects | Adult | Female | Leucovorin - therapeutic use | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Cetuximab | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Exons - genetics | Proto-Oncogene Proteins - genetics | Adenocarcinoma - drug therapy | Mucositis - chemically induced | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Intention to Treat Analysis | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Prevention | Care and treatment | Chemotherapy | Colon cancer | Hospitals | Leucovorin | Product development | Cancer | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
by Wagner, Anna Dorothea and Grabsch, Heike and Mauer, Murielle and Marreaud, Sanine and Caballero, Carmela and Thuss-Patience, Peter and Mueller, Lothar and Elme, Annelie and Moehler, Markus Hermann and Martens, Uwe and Kang, Yoon-Koo and Rha, Sun Young and Cats, Annemieke and Tokunaga, Masanori and Lordick, Florian
BMC cancer, ISSN 1471-2407, 05/2019, Volume 19, Issue 1, pp. 494 - 494
REGRESSION | SURGERY | OPEN-LABEL | OXALIPLATIN | DOCETAXEL | BREAST-CANCER | CAPECITABINE | Pertuzumab | NEOADJUVANT CHEMOTHERAPY | Gastro-esophageal junction cancer | Perioperative chemotherapy | HER2 | Gastric cancer | Trastuzumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - therapeutic use | Netherlands | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Esophageal Neoplasms - mortality | Adult | Female | Neoadjuvant Therapy | Republic of Korea | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Esophagogastric Junction - pathology | Treatment Outcome | Trastuzumab - administration & dosage | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Perioperative Period | Cisplatin - therapeutic use | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Chemotherapy | Usage | Gastrointestinal cancer | Dosage and administration | Comparative analysis | Drug therapy | Cancer | Immunohistochemistry | Care and treatment | Oncology, Experimental | Gastrointestinal system | Clinical trials | Metastasis | Research | Stomach cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
by Petrylak, Daniel P and de Wit, Ronald and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor J and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Chi, Kim Nguyen and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Laestadius, Fredrik and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Bamias, Aristotelis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Peer, Avivit and Sarid, David and Scagliotti, Giorgio Vittorio and Sternberg, Cora N and Tortora, Giampaolo and Bracarda, Sergio and Necchi, Andrea and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Matsubara, Nobuaki and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and ... and RANGE study investigators and RANGE Study Investigators
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Open-label placebo response – Does optimism matter? A secondary-analysis of a randomized controlled trial
by Locher, Cosima and Frey Nascimento, Antje and Kossowsky, Joe and Meyer, Andrea and Gaab, Jens
Journal of psychosomatic research, ISSN 0022-3999, 01/2019, Volume 116, pp. 25 - 30
Pain | Open-label placebos | Dispositional optimism | Personality-related variables | Individual differences | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Young Adult | Optimism - psychology | Placebo Effect | Humans | Middle Aged | Adolescent | Adult | Female | Male | Aged | Research Design | Variables | Analgesia | Heat | Pain perception | Tolerance | Personality | Optimism | Randomized controlled trials | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy
by Lichtiger, S and Binion, D. G and Wolf, D. C and Present, D. H and Bensimon, A. G and Wu, E and Yu, A. P and Cardoso, A. T and Chao, J and Mulani, P. M and Lomax, K. G and Kent, J. D
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 11/2010, Volume 32, Issue 10, pp. 1228 - 1239
Gastroenterology & Hepatology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Digestive system | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Other diseases. Semiology | Humans | Abscess | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Fistula | Antibodies, Monoclonal, Humanized | Anti-Inflammatory Agents - adverse effects | Infliximab | Efficiency | Crohn Disease - drug therapy | Quality of Life | Work | Adult | Female | Adalimumab | Wound Healing - drug effects | Clinical trials | Care and treatment | Crohn's disease | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Systemic therapy for vulval Erosive Lichen Planus (the 'hELP' trial): Study protocol for a randomised controlled trial
by Simpson, Rosalind C and Murphy, Ruth and Bratton, Daniel J and Sydes, Matthew R and Wilkes, Sally and Nankervis, Helen and Dowey, Shelley and Thomas, Kim S
Trials, ISSN 1745-6215, 01/2016, Volume 17, Issue 1, pp. 2 - 2
Pilot | Vulval | Multi-armed | Therapy | Pragmatic | Dermatology | Randomised controlled trial | Open-label | Erosive lichen planus | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Data Interpretation, Statistical | Pilot Projects | Vulvar Diseases - drug therapy | Outcome Assessment (Health Care) | Vulvar Diseases - psychology | Humans | Clinical Protocols | Lichen Planus - psychology | Quality of Life | Female | Lichen Planus - drug therapy | Care and treatment | Analysis | Clinical trials | Research | Lichen planus | Health aspects | Immunosuppressive agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights